alpha-glutamyltryptophan has been researched along with Acquired Immune Deficiency Syndrome in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (33.33) | 18.2507 |
2000's | 2 (66.67) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Aboulafia, D; Dezube, BJ; Gill, P; Lee, J; Noy, A; Scadden, DT; Tulpule, A; Walmsley, S | 1 |
Kisin, AV; Krugliak, IuL; Kurochkin, VK; Malekin, SI; Nosova, VM; RiakhovskiÄ, VV | 1 |
1 trial(s) available for alpha-glutamyltryptophan and Acquired Immune Deficiency Syndrome
Article | Year |
---|---|
Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi's sarcoma in a phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy: from the AIDS Malignancy Consortium and IM862 Study Team.
Topics: Acquired Immunodeficiency Syndrome; Administration, Intranasal; Adult; Aged; AIDS-Related Opportunistic Infections; Angiogenesis Inhibitors; Anti-HIV Agents; CD4 Lymphocyte Count; Dipeptides; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Middle Aged; Placebos; Remission Induction; Sarcoma, Kaposi; Self Administration; Viral Load | 2005 |
2 other study(ies) available for alpha-glutamyltryptophan and Acquired Immune Deficiency Syndrome
Article | Year |
---|---|
[Conjugates of 2',3'-didehydro-3'-deoxythymidine with thymogen. Synthesis and anti-HIV activity].
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Dipeptides; HIV-1; Humans; Peptides; Stavudine | 1999 |
AIDS-related Kaposi sarcoma trial is under way.
Topics: Acquired Immunodeficiency Syndrome; Advertising; Angiogenesis Inhibitors; Clinical Trials, Phase III as Topic; Dipeptides; Humans; Sarcoma, Kaposi | 2001 |